Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06528691 · ClinicalTrials.gov registry record · Phase 2
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
A Phase 2 study of High Grade Glioma and CNS Tumor, sponsored by St. Jude Children's Research Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 2
- Study locations
NCT06528691 is a Phase 2 study of High Grade Glioma and CNS Tumor that is actively recruiting participants, run by St. Jude Children's Research Hospital. The registered enrollment target is 52 participants, below the 64-participant average among 42 other High Grade Glioma trials with a reported enrollment target (19% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06528691, a Phase 2 study of High Grade Glioma and CNS Tumor, is actively recruiting participants, sponsored by St. Jude Children's Research Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 2
- Study locations
Study Summary
This clinical trial tests how well entrectinib works to treat patients less than 3 years of age with NTRK 1/2/3 or ROS1 fused, high grade glioma or other central nervous system (CNS) tumors.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Carboplatin
- DRUG Etoposide
- DRUG Entrectinib
- BIOLOGICAL G-CSF
Study Locations (2)
Tennessee
- St. Jude Children's Research Hospital - Memphis
Other
- King Hussein Cancer Center - Amman
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2026-04 |
| Est. Completion | 2032-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06528691
The ClinicalTrials.gov registry entry for NCT06528691 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 64-participant average among 42 other High Grade Glioma trials with a reported enrollment target (19% lower). The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with High Grade Glioma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT06528691 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Tennessee, Other.
Frequently Asked Questions
What is clinical trial NCT06528691 about?
NCT06528691 is a clinical study titled "Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors". This clinical trial tests how well entrectinib works to treat patients less than 3 years of age with NTRK 1/2/3 or ROS1 fused, high grade glioma or other central nervous system (CNS) tumors.
What is the current status of trial NCT06528691?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2026-04. Estimated completion is 2032-11.
What conditions does trial NCT06528691 study?
This clinical trial studies the following conditions: High Grade Glioma, CNS Tumor.
What interventions are being tested in trial NCT06528691?
The interventions under investigation include: Cyclophosphamide (DRUG), Carboplatin (DRUG), Etoposide (DRUG), Entrectinib (DRUG), G-CSF (BIOLOGICAL).
Who is sponsoring clinical trial NCT06528691?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06528691 being conducted?
This trial has 2 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
RECRUITING · Phase 2
-
Study of Olutasidenib and Temozolomide in HGG
RECRUITING · Phase 2
-
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
ACTIVE NOT RECRUITING · Phase 2
-
Low Dose Radiation Therapy for Glioblastoma Multiforme
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.